Therapies that suppress RIPK1 kinase activity are emerging as promising therapeutic agents for the treatment of multiple inflammatory disorders. The ability to directly measure drug binding of a RIPK1 inhibitor to its target is critical for providing insight into pharmacokinetics, pharmacodynamics, safety and clinical efficacy, especially for a first-in-class small-molecule inhibitor where the mechanism has yet to be explored.
necrosis factor (TNF) receptor pathway, which must be tightly regulated to maintain tissue homeostasis. If dysregulated, the TNF receptor pathway may result in spontaneous and robust inflammation. 7, 34 Recent work has shown that RIPK1 kinase activity can drive this inflammation through directly regulating necroptosis and proinflammatory cytokine production. 4, 5, 11, 14 The regulatory role of RIPK1 is not limited to only TNF receptor signaling, but is a critical driver of inflammation downstream of several other receptor pathways, including FasL, TRAIL, TLR3, and TLR4. 6, 23, 25 Recent literature describing the use of selective RIPK1 inhibitors and RIPK1 kinasedead knock-in mice in preclinical models have highlighted the pathogenic role for RIPK1 kinase activity, particularly in diseases associated with aberrant TNF receptor signaling. 3, 19, 36 Hence, we believe that blocking this pathway with RIPK1 small-molecule inhibitors has the potential to result in a broad therapeutic application in multiple inflammatory diseases including psoriasis, ulcerative colitis, and rheumatoid arthritis.
A series of RIPK1 inhibitors was first discovered using a phenotypic cell screen to identify compounds that block necroptotic cell death. 9, 10 We have recently reported on a number of potent inhibitors of RIPK1 kinase activity 2, 20, 21 An initial DNA-encoded library screen yielded the benzodiazepinone (BOAz) series of potent and highly selective RIPK1 kinase inhibitors. 20 Optimization of this series identified GSK2982772 which has nanomolar potency, exquisite selectivity and an excellent preclinical pharmacokinetic and developability profile leading to its selection for clinical development as a first-in-class small-molecule inhibitor for the treatment of inflammatory disease. 22 As with any new area of therapeutic intervention, it is not only critical to have a high-quality molecule, but it is also important to have methods to monitor direct target engagement to properly guide dose selection and interpret pharmacodynamic effects and clinical efficacy. 27 One of the main issues in monitoring drug efficacy during early clinical development is that drug binding is difficult to measure in cells and tissues. 26 Traditionally, drug efficacy has been monitored indirectly by assessing cellular responses downstream of the target protein. This can be rather simple if the target protein has a physiological function that is directly tied to alterations in circulating factors such as cytokines or chemokines in the blood. This becomes increasingly difficult, however, when measurement of drug efficacy is required at the tissue site of action where protein functions may not be easily measured. The FREE-RIPK1 immunoassay is no longer able to detect RIPK1
protein likely due to structural alterations in the RIPK1 activation loop, the region of epitope recognition by the FREE-RIPK1 antibody.
In this article, we describe the identification of the TEAR1 assay and its potential application for monitoring direct target engagement of BOAz-RIPK1 inhibitors in clinical tissue samples from patients with inflammatory disease.
| MATERIALS AND METHODS

| Reagents
RIPK1 inhibitors were developed at GlaxoSmithKline (Collegeville, 
| Animals
Eight healthy male cynomolgus macaques (Macaca fasicularis), age 
| Analytical methods for GSK'253
Analysis of blood samples from study days for GSK'253 was performed using liquid chromatography-tandem mass spectrometric (LC- 
| Tissue homogenization
Nonhuman primate tissues were transferred to prefrozen (À80°C) 
| Statisical analysis
Statistical analysis was performed using GraphPad Prism V6.0.
Unless otherwise specified, data are presented as mean AE SD. Comparisons were performed with a Student's t test whose values are represented in the figures as *P < .05, **P<.01, and ***P<.001.
| Ethics Statement
The animals were housed and maintained in accordance with stan- inhibitor-protein complex suggesting that these regions become less ordered than in the GSK'064 complex or are potentially blocked by the hinge-binding GSK'064. These structural changes in RIPK1 protein upon BOAz-RIPK1 inhibitor binding were confirmed with our recently published cocrystal structure data using GSK'481. 21 
| The selective RIPK1 inhibitors, GSK2882481
and GSK3011253, compete with antibody binding to RIPK1 protein
On the basis of the changes observed during our HDX-MS studies and co-crystallization efforts, we hypothesized that these changes in RIPK1 structure might be leveraged to monitor compound binding to RIPK1 protein using an immunoassay format with similarity to an assay that was developed for Bruton's tyrosine kinase. 13 To identify antibodies whereby the antibody binding is potentially altered when a RIPK1 inhibitor is present, we screened commercially available antibodies ( Figure 1A ; Table S1 ) in a sandwich immunoassay format using a mouse anti-human RIPK1 antibody to immunoprecipitate This assay has been termed the TEAR1 assay.
| Engagement of RIPK1 can be detected in cells using the TEAR1 assay
We sought to perform a similar set of compound experiments in HT29 cells using the TEAR1 assay. We focused on the GSK'253 RIPK1 inhibitor as it has better oral pharmacokinetic properties than GSK'481. As shown in Figure 2A , Based on the measured drug concentrations in the blood, RIPK1
target engagement was predicted using the IC 50 of 3.1 ngÁmL À1 for GSK'253, as determined in previously established cell-based assays (data not shown). Immediately after infusion, blood-drug levels had an observed Cmax of 197 AE 72 ngÁmL À1 ( Figure 3B ). Maximal target engagement was predicted to reach 98.3 AE 0.6% based on the observed Cmax with predicted levels decreasing to 14.6 AE 8.1% by 48 hours postinfusion ( Figure 3C ). Observed RIPK1 target engagement closely matched the predicted target engagement based on drug PK ( Figure 3C ; Table S2 ). GSK'253 demonstrated an IC 50 of 3.1 ngÁmL À1 matching that which was predicted from cell-based assays ( Figure 3D ).
To better define the utility of the TEAR1 assay in a clinically relevant target tissue associated with psoriasis, we analyzed skin biopsy samples and compared the observed target engagement to predicted target engagement based on tissue PK. Immediately after infusion, drug levels in the skin had an observed Cmax of 108 AE 39 ngÁmL
À1
( Figure 4A , Table S3 ). Maximal target engagement was predicted to reach 96.9 AE 1.0% based on the observed Cmax with predicted levels decreasing to 25.8 AE 17.9% by 48 hours postinfusion (Figure 4B ). Observed target engagement in skin biopsies correlated well with predicted target engagement based on tissue PK (Table S3) . At early time points (ie, 4 and 19 hours), target engagement was overestimated based on drug concentrations vs what was measured in the tissue using the TEAR1 assay, whereas at later time points (ie, 30 and 48 hours), predicted and observed levels were similar. These data suggest a time-dependent transit of the RIPK1 inhibitor to its target protein.
To expand our tissue target engagement analysis beyond skin samples, we evaluated RIPK1 target engagement in colon and synovial tissues, as these tissues are the major sites of inflammation in TNF-dependent diseases such as ulcerative colitis and rheumatoid arthritis, respectively. Colon and synovial tissue samples were isolated from each cohort (n = 2/cohort) and analyzed using the TEAR1 F I G U R E 2 RIPK1 target engagement in HT-29 cells using the TEAR1 assay. (A) HT29 cells were incubated with either GSK'253 or GSK'064 for 24 hours. Cells lysates (20 lg) were analyzed for RIPK1 target engagement using both FREE-RIPK1 and TOTAL-RIPK1 immunoassays. FREE-RIPK1 levels were normalized to TOTAL-RIPK1 levels. Data are represented as the percent target engagement AESD; n = 3 replicates per group. *P < .05, **P < .01, and ***P < .001. (B) HT29 cell lysates (10 lg) was analyzed by western blot for RIPK1 (CS3493, ab125072, and ab72139) and normalized to actin assay. After infusion, observed drug levels in the colon ( Figure 4C and Table S4 ) and synovium ( Figure 4D and Table S5 ) were similar to the predicted levels based on tissue PK.
| DISCUSSION
RIPK1 has emerged as an significant drug target for the treatment of a number of inflammatory disorders ranging from TNF-mediated diseases such as ulcerative colitis and multiple sclerosis, to ischemic events such as myocardial infarction and stroke, to acute criticalcare situations such as burn injury, sepsis, and toxic epidermal necrolysis. 12, 28, 29, [31] [32] [33] 35 We have previously reported on identification of GSK2982772 as a novel, potent, ultraselective inhibitor of RIPK1 22 that has recently completed Phase 1 safety and tolerability studies in healthy volunteers 15 and is currently being explored in Phase 2a experimental medicine studies for the treatment of psoriasis, 16 ulcerative colitis, 17 and rheumatoid arthritis. 18 As GSK2982772
is the first RIPK1 inhibitor to enter human clinical trials, being able detects the presence of drug-free BTK protein. 13 In this study, we describe a closely similar set of assays for assessing target engagement to RIPK1 protein, an assay we term the TEAR1 assay.
We have previously shown that RIPK1 protein undergoes significant structural alterations in the presence of our highly selective nizes an epitope C-terminal to the FREE-RIPK1 epitope and is less likely to undergo a conformational change in the presence of this inhibitor series, however, this has yet to be proven using structural studies, as the epitope (amino acid region 300-450) resides in regions which are not contained in our crystal structure (amino acid region 1-294). Together, using this set of two immunoassays measuring FREE-RIPK1 and TOTAL-RIPK1, the TEAR1 assay monitors Moving forward, the TEAR1 assay will be used in early clinical development to validate its utility to monitor target engagement in blood during phase 1 studies and to monitor target engagement in disease-relevant target tissues in future phase 2/3 proof-of mechanism and proof-of-concept studies. Having the ability to quantify target engagement in these studies using the TEAR1 assay will be invaluable in interpreting clinical studies with these novel RIPK1 inhibitors and understanding the relationship between target engagement, pathway inhibition, and clinical response. 
